Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

Prior treatment

• Patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of MRI

Other illness

• Uncontrolled hypertension
• Patient who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers of non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.

Lab values

• Hemoglobin \<10 g/dL
• Plasma albumin \<3 g/dL
• Plasma glucose \>200 mg/dL
• Renal insufficiency with plasma creatinine \>1.6
• Patient does not meet medical clearance for surgery and is not considered an appropriate surgical candidate

Other

• GOG performance status \>2
• Pregnancy
  • For Stage 2:

• The study population will include women with stage IB1 cervical cancer (any histologic subtype) deemed eligible for surgery, and women with a clinical stage I high-grade endometrial cancer planning to undergo surgical staging. High grade is defined by the following:
  • Uterine serous carcinoma
  • Clear cell endometrial carcinoma
  • Grade 3 endometrioid carcinoma
  • Endometrial carcinosarcoma
  • Clinical stage I grade 1-2 endometrial cancer also eligible with deep myoinvasion ≥ 50% shown on preop MRI and/or elevated preop CA-125 \> 35 U/ml.
• Age ≥18 years
• Hemoglobin ≥10 g/dL
• Plasma albumin ≥3 g/dL
• GOG performance status ≤2
• Plasma glucose ≤200 mg/dL
• Plasma creatinine ≤1.6
• Well-controlled hypertension
• Medical clearance for surgery and considered an appropriate surgical candidate
• Negative serum pregnancy test, if of child-bearing potential
• If, based on surgeon's assessment, the patient is recommended to undergo surgical staging for histologically confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease
• Participation in other research protocols does not exclude a patient from participation in this study